Current developments in the treatment of follicular germinal center lymphomas;Aktuelle entwicklungen in der therapie follikulärer keimzentrumslymphome

Onkologe

Volumn 7, Issue 9, 2001, Pages 969-981

  Hiddemann, W ^a,b   Dreyling, M ^a,b   Unterhalt, M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; MITOXANTRONE; PREDNIMUSTINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; FOLLICULAR LYMPHOMA; GERMINAL CENTER; HUMAN; NONHODGKIN LYMPHOMA; PATHOGENESIS; REVIEW; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY;

EID: 0034799373     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007610170045     Document Type: Review

References (95)

1. World Health Organization classification of neoplastic diseases of the hematopoetic and lymphoid tissues: Report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
3. Bcl-2 initiates a new category of oncogenes regulators of cell death
4. Involvement of the bcl-2 gene in human follicular lymphoma
5. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18)
6. Regulation of chemoresistance by bcl-2 oncoprotein in non-Hodgkin's lymphoma and lyphomcytic leukemia cell lines
7. Epidemiology of non-Hodgkin's lymphoma: Recent findings regarding an emerging epidemic
8. Strategien der bahandlung von non-Hodgkin-lymphomen
9. The natural history of initially untreated low-grade non-Hodgkin's lymphomas
10. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margret Hospital experience
11. Analysis of non-Hodgkin's lymphomas with nodular and favorable histologies stage I and II
12. Stage I-II follicular lymphoma, treatment results for 56 patients
13. Is radiotherapy curative for stage I and II low grade follicular lymphoma? Results of a long term follow-up study of patients treated at Stanford University
14. Extended field and total central lymphatic radiotherapy for early stages nodal centroblastic-centrocytic lymphoma: Results of a prospective multicenter study
15. Non-Hodgkin lymphomas (NHL) - Early stages: Interim results of a multi-centre trial
16. Stage III follicular lymphoma: Durable remissions with a combined chemotherapy-radiotherapy regimen
17. High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma
18. Limited stage I and II follicular non-Hodgkin's lymphoma: The Nebraska Lymphoma Study group experience
19. Randomized study of chlorambucil (CB) compared to interferon (alpha-2b) combined with CB in low-grade non-Hodgkin's lymphoma: An interim report of a randomized study
20. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma
21. Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low-grade lymphomas: An intergroup phase III trial (CALGB 8691 ans EST 7486)
22. Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's kynogina
23. A doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: Final analysis of survival and toxicity in the GELF 86 trial
24. Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherpy
25. Interferon alpha 2b as maintenance therapy in low grade malignant lymphoma improves duration of remission and survival
26. Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma
27. Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest oncology group - Randomized phase III study 8809
28. A meta-analysis of randomized trials evaluating the role of interferon as treatment for follicular lymphoma
29. Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion
30. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for follicular lymphoma
31. Autologous bone marrow transplantation as consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: A pilot study of 34 cases
32. Sequential high-dose therapy with peripheral-blood progenitor-cell support in low-grade non-Hodgkin's lymphoma
33. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
34. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
35. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: Results of a phase II clinical trial
36. Value of autologous stem-cell trans-plantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: A GOELAMS phase II study
37. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in prospective GELF 86 protocol
38. Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft
39. Secondary leukaemia and myelodysplasia after autografting for lymphoma: Results from the EBMT. EBMT lymphoma and late effects working parties
40. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autlogous hematopoetic progenitor-cell support for lymphoid malignancies
41. Myeloablative radiochemotherapy followed by blood-stemcell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: Results of a prospective randomized comparison by the German Low Grade Lymphoma Study Group (GLSG)
42. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low grade non-Hodgkin's lymphoma
43. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients responded to a four-dose treatment program
44. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory agressive lymphoma: A multicenter phase II study
45. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced stage follicular lymphomas: Results of a phase II study of the german low grade lymphoma study group
46. Chemoimmunotherapy of low-grade lymphoma with the anti-CD20 antibody IDEC-C2B8 in combination with CHOP chemotherapy
47. Pilot efficacy studies of rituximab in combination with chemotherapy, biologicals or radioimmunotherapy
48. Treatment of Patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
49. The incidence of cardiovascular disease in hetero-zygotes for HFE mutations attending a health appraisal clinic
50. Jodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma
51. 1311-B1 (anti-CD-20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas
52. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
53. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem-cell transplantation for relapsed B-cell lymphomas
54. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
55. Allogeneic bone marrow transplantation for low-grade lymphoma
56. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia
57. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
58. Role of radiation therapy in localized non-Hodgkin's lymphoma
59. Management of localized non-Hodgkin's lymphoma: The experience at St. Bartholomew's Hospital 1972-1985
60. Stage I-II low grade non-Hodgkin's lymphoma: Prognostic factors and treatment results
61. Central lymphatic irradiation for stage III nodular malignant lymphoma: Long-term results
62. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediategrade non-Hodgkin lymphoma. Results of a prospective randomized study
63. Stage III nodular lymphoreticular tumors (non-Hodgkin's lymphoma): Results of central lymphatic irradiation
64. The role of radiation therapy in the management of stage III follicular lymphomas
65. Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University
66. High-dose pulse chlorambucil in advanced, low-grade non-Hodgkin's lymphoma
67. High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin's lymphomas: A 5-year follow-up
68. Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone
69. Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors
70. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: Prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only - A preliminary update of the German Low-Grade Lymphoma Study Group
71. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma
72. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy
73. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicinbased chemotherapy or chemoimmunotherapy
74. Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index
75. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model
76. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin-vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis
77. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies
78. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma
79. Updated clinical experience with MACOP-B
80. Clinical features and prognosis of follicular large-cell lymphoma: A report from the Nebraska Lymphoma Study Group
81. A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma
82. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
83. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia
84. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
85. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: A GELA study
86. Efficacy and toxicity of 2-Chlorodeoxyadenosine (Cladribine)-2 h infusion for 5 days-as first-line treatment for advanced low grade non-Hodgkin's lymphoma
87. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma
88. Interferon alfa for the treatment of follicular lymphomas
89. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma
90. Maintenance of remission with human recombinant alpha-2 interferon (Roferon-A) in patients with stages III and IV low grade malignant non-Hodgkin's lymphoma. Results from a prospective, randomised phase III clinical trial in 331 patients
91. Combination chemotherapy prolongs survival in follicular mixed lymphoma (FML)
92. Fludarabine versus conventional CVP chemotherapy in newly diagnosed patients with stages III and IV low grade malignant Non-Hodgkin's Lymphoma. Preliminary results from a prospective, randomized phase III clinical trial in 381 patients
93. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the groupe d'etude des lymphomes de i'adulte
94. Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden
95. Interferon a2b in the treatment of follicular lymphoma: Preliminary results of a trial in progress